ArticlePediatric nephrology (Berlin, Germany)2025
Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases.Frontiers in immunology · 2026Pooled it
- Anti-rituximab antibodies: implications for clinical outcomes and safety in pediatric idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Optimal selection and timing of steroid-sparing therapy in childhood nephrotic syndrome: what determines long-term outcomes of adult survivors?Pediatric nephrology (Berlin, Germany) · 2026Article
- Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies.Pediatric nephrology (Berlin, Germany) · 2026Article
- Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.Drug design, development and therapy · 2026Article
- Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRituximab-induced serum sickness (RISS) is a rare drug complication in patients with steroid-dependent nephrotic syndrome (SDNS). CASE-DIAGNOSIS/TREATMENT: A 7-year-old boy with SDNS exhibited RISS recurrence 8 days after the third rituximab dose. At that time, the patient's antirituximab antibody (ARA) level was extremely high at > 5000 ng/mg, and his serum rituximab drug level was undetectable at < 0.2 μg/mL. Further, the patient had an early relapse with a short B-cell depletion period after the third rituximab dose. To address ARA-mediated rituximab resistance, a single infusion of obinutuzumab at a dose of 300 mg/m
conclusionsLow-dose obinutuzumab can be an effective and safe option for rituximab-resistant SDNS complicated by RISS and the development of ARA.
Indexed as
Identifiers
39966139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.